Clostridioides difficile -Associated Antibiotics Alter Human Mucosal Barrier Functions by Microbiome-Independent Mechanisms

Abstract

A clinically relevant risk factor for Clostridioides difficile-associated disease (CDAD) is recent antibiotic treatment. Although broad-spectrum antibiotics have been shown to disrupt the structure of the gut microbiota, some antibiotics appear to increase CDAD risk without being highly active against intestinal anaerobes, suggesting direct nonantimicrobial effects. We examined cell biological effects of antibiotic exposure that may be involved in bacterial pathogenesis using an in vitro germfree human colon epithelial culture model. We found a marked loss of mucosal barrier and immune function with exposure to the CDAD-associated antibiotics clindamycin and ciprofloxacin, distinct from the results of pretreatment with an antibiotic unassociated with CDAD, tigecycline, which did not reduce innate immune or mucosal barrier functions. Importantly, pretreatment with CDAD-associated antibiotics sensitized mucosal barriers to C. difficile toxin activity in primary cell-derived enteroid monolayers. These data implicate commensal-independent gut mucosal barrier changes in the increased risk of CDAD with specific antibiotics and warrant further studies in in vivo systems. We anticipate this work to suggest potential avenues of research for host-directed treatment and preventive therapies for CDAD.

An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides difficile Colonization and Hinders Clearance

“…Part of our hypothesis for why there could have been increased histopathology scores in PEG-treated mice was because PEG was previously shown to disrupt the mucus layer in mice. However, recent studies demonstrated that broad-spectrum antibiotics can also disrupt the host mucosal barrier in mice ( 53 , 54 ). Further research is needed to tease out the interplay between medications that influence the mucus layer and different strains of C. difficile in the context of CDIs.…”

Antibiotic use and risk of colorectal cancer: a systematic review and dose–response meta-analysis

“…Yet, the microbial dysbiosis observed among CRC patients in some studies, 48 supports the biological plausibility of broad-spectrum antibiotics having a long-term effect on the gut microbiota, potentially facilitating colonisation with pathogenic bacteria to a greater extent than narrow-spectrum antibiotics. 43,[48][49][50] Emerging amount of evidence from human and animal models suggests that dysbiosis, and particularly some bacteria strains (e.g. Bacterioides fragilis, Escherichia coli and Fusobacterium nucleatum), might involve a higher CRC risk through mechanisms increasing cancer promotion by altering cell proliferation, differentiation and apoptosis, inflammation, and production of DNA damaging toxins.…”

A Double-Edged Sword: Thioxanthenes Act on Both the Mind and the Microbiome

“…Novel, powerful systems which mimic the in vivo interaction between a microorganism and the host (represented by immortal cells, stem cells or even primary cells in mono or co-cultures) are being developed [ 111 , 112 , 113 , 114 , 115 ]. These systems will allow the rapid and efficient testing of the full effects of non-antibiotics in close to in vivo environments.…”